KRAS: From undruggable to a druggable Cancer Target

Cited by (273)

Items 101–200 of 273

1. Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment
   Zhaoyong Han, Ding Zhou, JiaMan Wang, Bruce Jiang, XiYu Liu · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
2. Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong In Vitro and In Vivo Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers
   Diana Fernandes de Sousa Rafael, Sara Montero, Pilar Carcavilla, Fernanda Andrade, Júlia German-Cortés, Zamira V. Díaz‐Riascos, Joaquin Seras‐Franzoso, Monserrat Llaguno Munive, Begoña Fernández, Alfredo Pereira et al. · 2023 · ACS Applied Materials & Interfaces
3. Dual inhibition of FOXM1 and its compensatory signaling pathway decreased the survival of ovarian cancer cells
   Dae Woo Lee, WeonSun Lee, Miyeon Kwon, Hae Nim Lee · 2020 · Oncology Reports
4. The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins
   Mingyue Mou, Wei‐Cheng Yang, Guangyi Huang, Xiaoyan Yang, Xiao Li Zhang, Wishwajith Kandegama, Charles R. Ashby, Ge‐Fei Hao, Yangyang Gao · 2025 · Medicinal Research Reviews
5. Inhibition of transforming growth factor‐β signals suppresses tumor formation by regulation of tumor microenvironment networks
   Shiori Tokizaki, Katarzyna A. Podyma‐Inoue, Takehisa Matsumoto, Kazuki Takahashi, Miho Kobayashi, Haruka Ibi, Shizuka Uchida, Sadahiro Iwabuchi, Hiroyuki Harada, Shinichi Hashimoto et al. · 2023 · Cancer Science
6. A novel method for detection of pancreatic Ductal Adenocarcinoma using explainable machine learning
   Murtaza Aslam, Fozia Rajbdad, Shoaib Azmat, Zheng Li, J. Philip Boudreaux, Ramcharan Thiagarajan, Shaomian Yao, Jian Xu · 2024 · Computer Methods and Programs in Biomedicine
7. Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide
   Yue Du, Xinrui Lin, Q. Feng, Xin-Yan Pan, Shu-Ling Song, Ju-Lun Yang · 2021 · Anti-Cancer Drugs
8. Hsa-miR-557 Inhibits Osteosarcoma Growth Through Targeting KRAS
   Zhi Qiao, Jinfeng Li, Hongwei Kou, Xiangrong Chen, Deming Bao, Guowei Shang, Songfeng Chen, Yanhui Ji, Tian Cheng, Yisheng Wang et al. · 2022 · Frontiers in Genetics
9. Identification of Novel circRNA-Based ceRNA Network Involved in the Pathogenesis of Gastric Cancer
   Dengfa Peng, Li Feng, Huqing Li · 2022 · International Journal of Genomics
10. What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy
    Paul M Hofman · 2021 · Journal of Molecular Pathology
11. Edible bird’s nest plays an immune regulation by influencing intestinal flora changes in mice
    Cui Li, Xiaohan Xu, Xiaoxian Lin, Man Yuan, Dongliang Wang, Xinke Zhang · 2024 · Journal of Functional Foods
12. Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review)
    Ling Wang, Jinjun Qian, Ye Yang, Chunyan Gu · 2021 · International Journal of Oncology
13. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras
    Gerhard Hamilton, Sandra Stickler, Barbara Rath · 2023 · Current Pharmaceutical Design
14. FAXC interacts with ANXA2 and SRC in mitochondria and promotes tumorigenesis in cholangiocarcinoma
    Haruna Fujimori, Mao Nakamura, Shin-ichiro Kanno, Rie Shibuya‐Takahashi, Mai Mochizuki, Masamichi Mizuma, Michiaki Unno, Yuta Wakui, Makoto Abue, Wataru Iwai et al. · 2024 · Cancer Science
15. Targeting the molecular chaperone CCT2 inhibits GBM progression by influencing KRAS stability
    Feihu Zhao, Zhong Yao, Yaquan Li, Wenbo Zhao, Yanfei Sun, Xiaobing Yang, Zhimin Zhao, Bin Huang, Jian Wang, Xingang Li et al. · 2024 · Cancer Letters
16. Targeting KRAS in gynecological malignancies
    Yuanyuan Peng, Qing fan Yang · 2024 · The FASEB Journal
17. Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
    Shenao Fu, Jiayao Ma, Changjing Cai, Jun Tan, Xiangying Deng, Hong Shen, Shan Zeng, Yihong Chen, Ying Han · 2025 · Journal of Experimental & Clinical Cancer Research
18. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRASG12C Inhibitors
    Lianxiang Luo, Tongyu Zheng, Qu Wang, Yingling Liao, Xiaoqi Zheng, Ai Zhong, Zunnan Huang, Hui Luo · 2022 · Pharmaceuticals
19. The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence
    Hua Sun, Xiaohui Qi · 2022 · Discover Oncology
20. Translational relevance of SOS1 targeting for KRAS‐mutant colorectal cancer
    Diego Alem, Xinrui Yang, Francisca Beato, Bhaswati Sarcar, Alexandra F. Tassielli, Ruifan Dai, Tara L. Hogenson, Margaret A. Park, Kun Jiang, Jianfeng Cai et al. · 2023 · Molecular Carcinogenesis
21. Precise Differentiation of Wobble-Type Allele via Ratiometric Design of a Ligase Chain Reaction-Based Electrochemical Biosensor for CYP2C19*2 Genotyping of Clinical Samples.
    Zhoujie Liu, Liang-Yong Yang, Tai-Cheng Lu, Chen Huang, Yu-Qi Liang, Xiong-Wei Xu, Yan-Fang Xu, Meng-Meng Liu, Xin-Hua Lin, Jinyuan Chen · 2023 · Analytical Chemistry
22. Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance
    Zhiyan Jiang, Yan Li, Xin Zhou, Jie Wen, Pengwu Zheng, Wufu Zhu · 2024 · Bioorganic & Medicinal Chemistry
23. ML‐Based Screening of miRNA Inhibitors and Intervention of lncRNA/miRNA/mRNA Axis in Oncogenic KRAS‐Associated Colorectal Cancer
    Prasanna Srinivasan Ramalingam, Deepak B. Thimiri Govinda Raj, Murugan Subramanian, Sivakumar Arumugam · 2024 · Advances in Public Health
24. KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
    Jiujie Cui, Kuirong Jiang, Wei Li, Shuqin Ni, Hong Zong, Juan Du, Yifu He, Zhonghua Liu, Guoqiang Kong, Yu Zhang et al. · 2026 · Nature Medicine
25. Multi-omics analysis of kinesin family member 2C in human tumors: novel prognostic biomarker and tumor microenvironment regulator.
    Bixi Zhang, Peng Liu, Yanchun Li, Qing Feng Hu, Huan Li, Xiaoyang Pang, Hao Wu · 2022 · PubMed Central
26. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
    Jimi Kim · 2023 · International Journal of Molecular Sciences
27. Multiple primary malignant neoplasm: Case report and comprehensive literature review
    Xueyan Ma, Kun Tian, Pengfei Sun · 2023 · Frontiers in Oncology
28. ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure
    Jamie Rijmers, Irene A. Retmana, Viët Bui, Davinia Arguedas, Maria Cristina Lebre, Rolf W. Sparidans, Jos H. Beijnen, Alfred H. Schinkel · 2024 · Biomedicine & Pharmacotherapy
29. Preclinical evaluation of targeted therapies for central nervous system metastases
    Alexander J. Pfeil, Joshua Hale, Tiger Zhang, Kentaro Wakayama, Isao Miyazaki, Igor Odintsov, Romel Somwar · 2024 · Disease Models & Mechanisms
30. EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
    Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, Azam Safary, Khosro Adibkia · 2025 · Scientific Reports
31. Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer
    Soo‐Yeon Hwang, Yoojeong Seo, Seojeong Park, Seul-Ah Kim, Inhye Moon, Yi Liu, Seojeong Kim, Eun Seon Pak, Sehyun Jung, Hyeyoon Kim et al. · 2025 · Molecular Cancer
32. The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma
    Guang-Xiao Meng, Chuncheng Yang, Lun‐Jie Yan, Yafei Yang, Yu‐Chuan Yan, Jian‐Guo Hong, Zhiqiang Chen, Zhao‐Ru Dong, Tao Li · 2023 · Heliyon
33. The Nanotechnology-Based Approaches against Kirsten Rat Sarcoma-Mutated Cancers
    Fernanda Andrade, Júlia German-Cortés, Sara Montero, Pilar Carcavilla, Diego Baranda-Martínez-Abascal, Marc Moltó‐Abad, Joaquin Seras‐Franzoso, Zamira V. Díaz‐Riascos, Diana Fernandes de Sousa Rafael, Ibane Abasolo · 2023 · Pharmaceutics
34. WWP1 inhibition increases SHP2 inhibitor efficacy in colorectal cancer
    Hao Fan, Xuefei Hu, Fuao Cao, Leqi Zhou, Rongbo Wen, Hao Shen, Yating Fu, Xiaoming Zhu, Hang Jia, Zixuan Liu et al. · 2024 · npj Precision Oncology
35. Breast Cancer: Circular RNAs Mediating Efficacy in PreclinicalIn VivoModels
    Ulrich H. Weidle, Hung‐En Hsia, Ulrich Brinkmann · 2023 · Cancer Genomics & Proteomics
36. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy.
    Dan-Dan Yang, Zhihui Duan, Ping Yuan, Cheng-Ming Ding, Xiaoming Dai, Guo-Dong Chen, Dai-Chao Wu · 2023 · Biochemical and Biophysical Research Communications - BBRC
37. A prognostic model for anoikis-related genes in pancreatic cancer
    Wenbin Song, Haiyang Hu, Zhengbo Yuan, Hao Yao · 2024 · Scientific Reports
38. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
    Mandana Kamgar, G. Aaron Hobbs, Raven Davidson, Daniel Dorbin, Juliannie Herrera, John Fairbanks Langenheim, Rachel A. Burge, Mohammed Aldakkak, Ryan D. Conrardy, Anikó Szabó et al. · 2025 · Cancer Research
39. Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1
    Lily Darman, Quinn Kaurich, Sazzad Hassan, Urs W. von Holzen, Niranjan Awasthi · 2025 · International Journal of Molecular Sciences
40. Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
    Matthew L. Condakes, Zhuo Zhang, Derek B. Danahy, Richard R. Moore, Sirish Kaushik Lakkaraju, Xiaoliang Zhuo, Yuka Amako, R. M. Borzilleri, Srividya B. Balachander, Lisa Sinang Chourb et al. · 2026 · Nature Communications
41. PDP1 Promotes Cell Malignant Behavior and Is Associated with Worse Clinical Features in Ovarian Cancer Patients: Evidence from Bioinformatics and In Vitro Level
    Yan Song, Juan Zhang, Lei Zhang, Suxia Zhang, Chengcheng Shen · 2022 · Computational and Mathematical Methods in Medicine
42. Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation
    Vida Tajiknia, Maximilian P. Pinho-Schwermann, Praveen R. Srinivasan, Liz J. Hernández Borrero, Leiqing Zhang, Kelsey E. Huntington, Wafik S. El‐Deiry · 2024 · American Journal of Cancer Research
43. Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics
    Gerhard Hamilton, Adelina Plangger · 2021 · Expert Opinion on Drug Metabolism & Toxicology
44. Relevance of BRAF Subcellular Localization and Its Interaction with KRAS and KIT Mutations in Skin Melanoma
    Marius Alexandru Beleaua, Ioan Jung, Cornelia Braicu, Doina Milutin, Simona Gurzu · 2021 · International Journal of Molecular Sciences
45. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Yanxia Liu, Yuan Jiao Gao, Ying Wang, Cong Zhao, Zhiyun Zhang, Baolan Li, Tongmei Zhang · 2022 · BMC Cancer
46. WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRASG12C-mutant lung cancer
    Chao Zhou, Yuqing Liu, Hongyu Liu, Jun Lü, Bo Zhang, Liang Zhu, Shuyuan Wang, Hui-min Lei, Baohui Han · 2025 · Cell Death and Disease
47. c-Myc/GRPEL1 maintains fatty acid synthesis via FASN to support PDAC cell proliferation
    Jing Wang, Liyuan Zhang, Keke Chen, F Z Wei, Wendi Li, Chanjuan Cui, Feng Chen, Bing Wei, Tao Huang, Hezhi Fang et al. · 2026 · Cell Death and Disease
48. Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma
    Xiang Zhou, Ran Xu, Tong Lu, Chenghao Wang, Xiaoyan Chang, Bo Peng, Zhiping Shen, Lingqi Yao, Kaiyu Wang, Chengyu Xu et al. · 2023 · Scientific Reports
49. Leveraging a KRAS-based signature to predict the prognosis and drug sensitivity of colon cancer and identifying SPINK4 as a new biomarker
    Jian-Ting Huo, Abudumaimaitijiang Tuersun, Su-Yue Yu, Yuchen Zhang, Wenqing Feng, Zhuoqing Xu, Jingkun Zhao, Yaping Zong, Aiguo Lu · 2023 · Scientific Reports
50. Identification and Analysis of Anticancer Therapeutic Targets from the Polysaccharide Krestin (PSK) and Polysaccharopeptide (PSP) Using Inverse Docking
    Carlos Iván Lopéz-Gil, Alejandro Téllez‐Jurado, Marco Antonio Velasco-Velázquez, Miguel Ángel Anducho-Reyes · 2024 · Molecules
51. Clinical implications of the molecular characterization of intraductal papillary mucinous neoplasms of the pancreas
    Nicholas V. Peters, John W. Kunstman · 2021 · Journal of Cancer Metastasis and Treatment
52. Diverse Functions of MiR-425 in Human Cancer
    Zhichao Wang, Wenjie Xie, Hongzai Guan · 2023 · DNA and Cell Biology
53. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations
    Andreas Nicholas Saltos, Ben Creelan, Tawee Tanvetyanon, Alberto Chiappori, Scott Joseph Antonia, Michael Rahman Shafique, Milijana Ugrenovic-Petrovic, Samer S. Sansil, Anthony M. Neuger, Hilal Özakıncı et al. · 2023 · Lung Cancer
54. Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP
    Yannan Xia, Shujie Zhang, Hongyi Luo, Yumeng Wang, Yuanyuan Jiang, Jingwei Jiang, Shengtao Yuan · 2023 · European Journal of Pharmacology
55. Searching for treatments for non-G12C-KRAS mutant cancers
    Christina W. Guo, Udai Banerji · 2021 · British Journal of Cancer
56. Revealing KRas4b topology on the membrane surface
    Shweta Shree, Mark A. McLean, Andrew G. Stephen, Stephen G. Sligar · 2023 · Biochemical and Biophysical Research Communications
57. Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy
    Yihao Wang, Nan Sun, Rui He, Zida Wang, Jingsi Jin, Ting Gao, Junwen Qu · 2024 · Clinical and Experimental Medicine
58. KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients
    Elena-Roxana Avădănei, Irina-Draga Căruntu, Irina Nucă, Raluca Anca Balan, Ludmila Lozneanu, Simona Eliza Giuşcă, Diana Lavinia Pricope, Cristina Gena Dascălu, Cornelia Amălinei · 2025 · Current Issues in Molecular Biology
59. K-ras proto-oncogene (KRAS): Evolutionary dissection on the indispensable predictive and prognostic cancer biomarker across 32 primates
    Leonard Whye Kit Lim · 2023 · Animal Gene
60. Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS
    Sadaf Dorandish, Komal Bhayekar, Anuradha Singh, Narva Deshwar Kushwaha, Evan Malin, Sara Serafimovski, Jeremy M. Kelm, Navnath S. Gavande, Naga Rajiv Lakkaniga · 2025 · RSC Medicinal Chemistry
61. Precision diagnostics in cancer: Predict, prevent, and personalize
    Judy S. Crabtree, Lucio Miele · 2022 · Progress in molecular biology and translational science
62. The Double-Edged Proteins in Cancer Proteomes and the Generation of Induced Tumor-Suppressing Cells (iTSCs)
    Kexin Li, Qingji Huo, Bai‐Yan Li, Hiroki Yokota · 2023 · Proteomes
63. Chronic exposure to low levels of phenanthrene induces histological damage and carcinogenic risk in the uterus of female mice
    Jie Sheng Huang, Ying Zhang, Lu Fang, Feifei Xi, Chen Tang, Kunlin Ou, Chonggang Wang · 2024 · Environmental Science and Pollution Research
64. Uncovering the molecular targets of phytocannabinoids: mechanistic insights from inverse molecular docking fingerprint approaches
    Vid Ravnik, Marko Jukič, Veronika Furlan, Uroš Maver, Jan Rožanc, Urban Bren · 2025 · Frontiers in Pharmacology
65. CYFIP2: potential pancreatic cancer biomarker and immunotherapeutic target
    Cong Xiao, Xiaojuan Zhang, Bobo Hou, Ping Wan, Zhenjun Cao, Xuefeng Rao · 2024 · Discover Oncology
66. Depletion-dependent activity-based protein profiling using SWATH/DIA-MS detects serine hydrolase lipid remodeling in lung adenocarcinoma progression
    Tatjana Sajic, Matej Vizovišek, Stephan Arni, Rodolfo Ciuffa, Martin Mehnert, Sébastien Lenglet, Walter Weder, Héctor Gallart‐Ayala, Julijana Ivanišević, Marija Buljan et al. · 2025 · Nature Communications
67. Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
    Chenyue Xu, Qiongmei Gao, ZhengMing Wu, Weijuan Lou, Xiaoyan Li, Nianhong Wang, Nianhong Wang, Qingquan Li · 2022 · Translational Oncology
68. Molecular and phenotypic spectrum of cardio-facio-cutaneous syndrome in Chinese patients
    Biyun Feng, Xin Li, Qianwen Zhang, Yirou Wang, Shili Gu, Ruen Yao, Zhiying Li, Shiyang Gao, Guoying Chang, Qun Li et al. · 2023 · Orphanet Journal of Rare Diseases
69. Drivers of Pancreatic Cancer: Beyond the Big 4
    Laura M. Porcza, Rafael Ballesteros-Cillero, Lok To Lam, Cristina Maiello, Nicholas R. Leslie · 2025 · Cancers
70. Integrated Analysis of the Role of Enolase 2 in Clear Cell Renal Cell Carcinoma
    Jiaren Pan, Yanyan Jin, Xiaoming Xu, Wei Wei, Huafeng Pan · 2022 · Disease Markers
71. Ras interacting protein 1 facilitated proliferation and invasion of diffuse large B-cell lymphoma cells
    Xiaojing Xing, Xuguang Wang, Meichen Liu, Qianxue Guo, Hongyue Wang · 2023 · Cancer Biology & Therapy
72. Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics
    Yuda Zhang, Fanxu Zeng, Shixuan Peng, Yangqian Chen, Wenjuan Jiang, Zhan Wang, Deng Li, Zhe Huang, Haoyue Qin, Huan Yan et al. · 2023 · Expert Review of Respiratory Medicine
73. Novel Tricyclic KRAS Inhibitors for the Treatment of Cancer
    Taoqian Zhao, Steven H. Liang · 2025 · ACS Medicinal Chemistry Letters
74. Elevated co-expression of TIMM17A and NMT1 is associated with poor survival in non-small cell lung cancer
    Alfred A. Chan, K. Nathan Sankar, Karen L. Reckamp, Begoña Díaz, Delphine J. Lee · 2025 · Scientific Reports
75. Optimization of Covalent Warhead Trajectory for KRAS G12C Active-State Inhibition
    Matthew L. Condakes, Rita L. Civiello, Sirish Kaushik Lakkaraju, Jack L. Sloane, Lisa Sinang Chourb, Daniel P. Downes, Dieter M. Drexler, Liudmila Dzhekieva, Miriam El-Samin, Christopher G. Levins et al. · 2026 · Journal of Medicinal Chemistry
76. Evolutionary screening of precision oncology biomarkers and its applications in prognostic model construction
    Zhiwen Zhang, Kexin Zhang, Xuan Liao, Quan Yuan, Hongyu Zhang · 2024 · iScience
77. Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on KRAS Mutation
    Alexander Siegman, Aaron Shaykevich, Danbee Chae, Isaac Silverman, Sanjay Goel, Radhashree Maitra · 2024 · Current Issues in Molecular Biology
78. Suite of Biochemical and Cell-Based Assays for the Characterization of Kirsten Rat Sarcoma (KRAS) Inhibitors and Degraders
    Medhanie Kidane, Rene M. Hoffman, Jennifer K. Wolfe-Demarco, Ting-Yu Huang, Chi-Ling Teng, Saheli Samanta, Luis M. Gonzalez Lira, Jennifer Lin‐Jones, Gabriel Pallares, Jane E. Lamerdin et al. · 2024 · ACS Pharmacology & Translational Science
79. The Distribution and Predictive Factor of Extra-Pancreatic Malignancy Occurrence in Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm—A Ten-Year Follow-Up Case–Control Study in Taiwan
    Sheng‐Fu Wang, Chi‐Huan Wu, Kai‐Feng Sung, Yung‐Kuan Tsou, Cheng-Hui Lin, Mu-Hsien Lee, Nai‐Jen Liu · 2024 · Cancers
80. Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
    Peiliang Dong, Jiating Ni, Xinyue Zheng, Mingtao Wang, Meng Yang, Hua Han · 2025 · European Journal of Pharmacology
81. Molecular Dynamics Investigation into the Stability of KRas and CRaf Multimeric Complexes
    Chongli Geng, Juan Zeng, Xianming Deng, Fei Xia, Xin Xu · 2025 · The Journal of Physical Chemistry B
82. Genetically druggable targets for MAPK-activated colorectal cancer by a two-sample mendelian randomization analysis
    Yuxuan Zhou, Yunlong Ding, Binghe Xu, H Fei, Zheng Wang · 2025 · Scientific Reports
83. KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications
    Anita Emami, Pouya Mahdavi Sharif, Nima Rezaei · 2025 · Expert Opinion on Therapeutic Targets
84. Pan-Cancer Analysis Identifies a Ras-Related GTPase as a Potential Modulator of Cancer
    Hsiang‐Yin Hsueh, Kristyn Gumpper, Jelmer W. Poelstra, Kenneth L. Pitter, Zobeida Cruz‐Monserrate · 2025 · International Journal of Molecular Sciences
85. KRAS oncogenic mutations in benign tumors: adenomatoid odontogenic tumor as a model
    Bruna Pizziolo Coura, Letícia Martins Guimarães, Ricardo Santiago Gomez, Carolina Cavaliéri Gomes · 2025 · Mutation Research/Reviews in Mutation Research
86. Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats
    Ping Du, Lihong Liu, Ting Hu, Zhuoling An · 2022 · Frontiers in Oncology
87. Recent advances in targeted degradation in the RAS pathway
    Zhiming Ge, Zisheng Fan, Wei He, Guizhen Zhou, Yidi Zhou, Mingyue Zheng, Sulin Zhang · 2025 · Future Medicinal Chemistry
88. High‐Frequency Mutations in TP53 , AXIN1 , CTNNB1 , and KRAS , and Polymorphisms in JAK1 Genes Among Mongolian HCC Patients
    Nomin Bold, Khurelsukh Buyanbat, Enkhtuya Ariya, Nomin Myagmar, Gerelsuren Batbayar, Zolzaya Sandag, Dolgion Damdinbazar, Nomuun Oyunbat, Tuul Boldbaatar, Enkhbaatar Ankhbayar et al. · 2025 · Cancer Reports
89. Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer
    Yunchang Li, Lanlin Hu, Chuan Shan Xu · 2021 · Current Opinion in Oncology
90. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer
    Phaedra C. Ghazi, Kayla T. O’Toole, Sanjana Srinivas Boggaram, Michael T. Scherzer, Mark R. Silvis, Yun Zhang, Madhumita Jagannathan‐Bogdan, Bryan D. Smith, Guillermina Lozano, Daniel Lee Flynn et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
91. Anticancer Target Combinations: Network- Informed Signaling-Based Approach to Discovery
    Bengi Ruken Yavuz, Hyunbum Jang, Ruth Nussinov · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
92. The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies
    Daniel F. Pilco‐Janeta, Myriam De la Cruz Puebla · 2025 · Anti-Cancer Drugs
93. Study on the carcinogenic risk of food preservatives and their related molecular targets and pathway mechanisms through network toxicology analysis
    Fuling Zeng, Jiaxin Zeng, Fuyan Lai · 2026 · Molecular Diversity
94. Proteolysis-targeting chimera (PROTAC) in cancer: design principles and applications on “undruggable” targets
    Xun Lu, Jianliang Qin, Shuilin Dong, Yue Yuan, Zhanguo Zhang, B Zhang, Xiaoping Chen, Xiaoli Gan, Huifang Liang, Furong Liu · 2026 · Biomarker Research
95. RETRACTED ARTICLE: The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression
    Disha V. Pandya, Rajsi V. Parikh, Ruhanahmed M. Gena, Nirjari R. Kothari, Priyajeet S. Parekh, Mehul R. Chorawala, Maharsh A. Jani, Mayur R. Yadav, Palak A. Shah · 2024 · Molecular Biology Reports · Retracted
96. Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS Pathway in Pancreatic Cancer
    Yanli Guo, Yu Jin, Jie Gao, Ding Wang, Yanming Wang, Liya Shan, Mengyu Yang, Xinzhi Li, Ketao Ma · 2024 · Pharmaceuticals
97. Advances in Synthetic Lethality in Potential Oncology Therapeutic Approaches
    Feifei Yang, Huiyu Wang, Shule Fan, Huiran Qiu, Xiangzhi Li, Guangyao Shi, Zihao Li, Xiaotian Luan, Haigang Wu · 2025 · Current Topics in Medicinal Chemistry
98. Identification of KRAS mutants (G12C, G12D, and G12V) inhibitors
    Vikas Yadav, Mohammad Kashif, Zenab Kamalia, Vikas, P R Santhipriya, Samudrala Gourinath, Neelima Mondal, Naidu Subbarao · 2025 · Future Medicinal Chemistry
99. Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway
    Namkyoung Kim, Injae Shin, Younghoon Kim, Eunhye Jeon, Ji‐Won Lee, Chaeyoung Lee, Yunju Nam, Sumin Lee, Eunhye Ju, Chan Kim et al. · 2021 · Frontiers in Oncology
100. Discussion on the Influence of Gpx 4 Target in the Field of Cancer
     Yalan Wang, Hongyan Guo, Tong Zhou, Ke Sun, Qing‐Kun Shen, Xiaoting Li · 2024 · Current Medicinal Chemistry